Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GATA zinc finger domain containing 2A (GATAD2A) is a protein-coding gene that encodes a subunit of the nucleosome remodeling and deacetylase (NuRD) complex, a crucial multi-protein complex involved in chromatin remodeling and transcriptional repression[1][5][7]. GATAD2A, also known as transcriptional repressor p66-alpha, functions as a protein-macromolecule adaptor within the NuRD complex, facilitating the negative regulation of DNA-templated transcription and gene silencing primarily through facilitating histone deacetylation[1][7]. It enhances MBD2-mediated repression and forms an efficient repressor complex in conjunction with GATAD2B. GATAD2A is localized to the nucleoplasm and is implicated in several cellular pathways, including DNA repair (homologous recombination) by recruiting the NuRD complex to sites of DNA damage[2]. Mutations and alterations in GATAD2A have been associated with cancer (notably sarcomas), dilated cardiomyopathy, and Sifrim-Hitz-Weiss syndrome, highlighting its relevance to disease but not as a direct drug target[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GATA zinc finger domain containing 2A (GATAD2A).